A Phase 1 interventional study of Placebo and Comparator: Amlodipine in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-09.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 159th largest by enrollment of the 186 interventional ones that give a count, is one of 12 that started in 2010, is one of 17 in phase 1, and was the 93rd registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 30 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 12 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
33 studies in Hypertension by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 33 finished, 27 (82%) have results posted.
Among the 33 studies in Hypertension by Merck & Co., Inc, this one is the 21st largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2010, is one of 17 in phase 1, and was the 21st registered.
Merck & Co., Inc’s Hypertension studies by the year they started, since 1990.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Merck & Co., Inc’s 33 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will test the relationship between CBP (central blood pressure) and PBP (peripheral blood pressure) effects after single and multiple doses of Isosorbide mononitrate extended release (ISMN ER) or Amlodipine besylate in participants with hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
and \<180 mm Hg
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER
Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER
Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER
Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER
Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER
Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule for 4 weeks during Period, with a 2-week washout between each period.
Drug: Placebo · Drug: Comparator: Amlodipine · Drug: Comparator: ISMN ER
Placebo, capsule taken orally once daily during 4 weeks of treatment
Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
Time-weighted Average (TWA) Change From Baseline (0 Hours) to 12 Hours in Heart-Rate-Corrected Augmentation Index (AIx) After A Single Dose of Treatment
The augmentation index (AIx) is a measure of systemic arterial stiffness, and is the ratio of augmented aortic pressure (Δ P) to central pulse pressure expressed as a percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. Single dose effects on AIx were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period. Because heart rate (HR) affects AIx, AIx was corrected to a HR of 75 beats per minute (bpm) as follows: HR-corrected AIx = -0.39 x (75 - HR) + AIx. This value was used for all AIx analyses.
Time frame: Baseline (0 hrs), 12 hours post-dose (Day 1)
Change From Baseline (0 Hours) to Week 4 in Heart-Rate-Corrected AIx After Multiple Doses of Treatment
The augmentation index (AIx) is a measure of systemic arterial stiffness, and is the ratio of augmented aortic pressure (Δ P) to central pulse pressure expressed as a percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. Because heart rate (HR) affects AIx, AIx was corrected to a HR of 75 beats per minute (bpm) as follows: HR-corrected AIx = -0.39 x (75 - HR) + AIx. This value was used for all AIx analyses.
Time frame: Baseline (0 hrs), 24 hours after the Day 28 dose
TWA Change From Baseline (0 Hours) to 12 Hours in Central Systolic Blood Pressure (SBP) After A Single Dose of Treatment
Central SBP was measured by the SphygmoCor® device. Single dose effects on central SBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.
Time frame: Baseline (0 hrs), 12 hours post-dose (Day 1)
Change From Baseline (0 Hours) to Week 4 in Central SBP After Multiple Doses of Treatment
Central SBP was measured by the SphygmoCor® device. Central SBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.
Time frame: Baseline (0 hrs), 24 hours after the Day 28 dose
TWA Change From Baseline (0 Hours) to 12 Hours in Central Diastolic Blood Pressure (DBP) After A Single Dose of Treatment
Central DBP was measured by the SphygmoCor® device. Single dose effects on central DBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.
Time frame: Baseline (0 hrs), 12 hours post-dose (Day 1)
Change From Baseline (0 Hours) to Week 4 in Central DBP After Multiple Doses of Treatment
Central DBP was measured by the SphygmoCor® device. Central DBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.
Time frame: Baseline (0 hrs), 24 hours after the Day 28 dose
TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral SBP After A Single Dose of Treatment
Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Single dose effects on peripheral SBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.
Time frame: Baseline (0 hrs), 12 hours post-dose (Day 1)
Change From Baseline (0 Hours) to Week 4 in Peripheral SBP After Multiple Doses of Treatment
Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Peripheral SBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.
Time frame: Baseline (0 hrs), 24 hours after the Day 28 dose
TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral DBP After A Single Dose of Treatment
Peripheral DBP was measured by Brachial Sphygmomanometer (standard cuff). Single dose effects on peripheral DBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.
Time frame: Baseline (0 hrs), 12 hours post-dose (Day 1)
Change From Baseline (0 Hours) to Week 4 in Peripheral DBP After Multiple Doses of Treatment
Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Peripheral DBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.
Time frame: Baseline (0 hrs), 24 hours after the Day 28 dose
| Milestone | Placebo/ISMN ER/Amlodipine (Sequence 1) | ISMN ER/Amlodipine/Placebo (Sequence 2) | Amlodipine/Placebo/ISMN ER (Sequence 3) | ISMN ER/Placebo/Amlodipine (Sequence 4) | Placebo/Amlodipine/ISMN ER (Sequence 5) | Amlodipine/ISMN ER/Placebo (Sequence 6) |
|---|---|---|---|---|---|---|
| Started | 6 | 7 | 6 | 8 | 5 | 6 |
| Completed | 6 | 6 | 5 | 5 | 5 | 6 |
| Not completed | 0 | 1 | 1 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Discontinued for other reason | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Placebo/ISMN ER/Amlodipine (Sequence 1) | ISMN ER/Amlodipine/Placebo (Sequence 2) | Amlodipine/Placebo/ISMN ER (Sequence 3) | ISMN ER/Placebo/Amlodipine (Sequence 4) | Placebo/Amlodipine/ISMN ER (Sequence 5) | Amlodipine/ISMN ER/Placebo (Sequence 6) |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 5 | 5 | 5 | 6 |
| Completed | 6 | 6 | 5 | 5 | 5 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo/ISMN ER/Amlodipine (Sequence 1) | ISMN ER/Amlodipine/Placebo (Sequence 2) | Amlodipine/Placebo/ISMN ER (Sequence 3) | ISMN ER/Placebo/Amlodipine (Sequence 4) | Placebo/Amlodipine/ISMN ER (Sequence 5) | Amlodipine/ISMN ER/Placebo (Sequence 6) |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 5 | 5 | 5 | 6 |
| Completed | 6 | 6 | 5 | 5 | 5 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
The augmentation index (AIx) is a measure of systemic arterial stiffness, and is the ratio of augmented aortic pressure (Δ P) to central pulse pressure expressed as a percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. Single dose effects on AIx were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period. Because heart rate (HR) affects AIx, AIx was corrected to a HR of 75 beats per minute (bpm) as follows: HR-corrected AIx = -0.39 x (75 - HR) + AIx. This value was used for all AIx analyses.
| percent | ISMN ER | Amlodipine | Placebo |
|---|---|---|---|
| Time-weighted Average (TWA) Change From Baseline (0 Hours) to 12 Hours in Heart-Rate-Corrected Augmentation Index (AIx) After A Single Dose of Treatment | -11.1 ± 4.5 | -0.7 ± 4.5 | 2.1 ± 4.5 |
The augmentation index (AIx) is a measure of systemic arterial stiffness, and is the ratio of augmented aortic pressure (Δ P) to central pulse pressure expressed as a percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. Because heart rate (HR) affects AIx, AIx was corrected to a HR of 75 beats per minute (bpm) as follows: HR-corrected AIx = -0.39 x (75 - HR) + AIx. This value was used for all AIx analyses.
| percent | ISMN ER | Amlodipine | Placebo |
|---|---|---|---|
| Change From Baseline (0 Hours) to Week 4 in Heart-Rate-Corrected AIx After Multiple Doses of Treatment | 2.5 ± 6.2 | -4.7 ± 6.2 | 1.2 ± 6.2 |
Central SBP was measured by the SphygmoCor® device. Single dose effects on central SBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.
| mm mercury (Hg) | ISMN ER | Amlodipine | Placebo |
|---|---|---|---|
| TWA Change From Baseline (0 Hours) to 12 Hours in Central Systolic Blood Pressure (SBP) After A Single Dose of Treatment | -14.7 ± 7.7 | -3.6 ± 7.7 | 2.7 ± 7.7 |
Central SBP was measured by the SphygmoCor® device. Central SBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.
| mm mercury (Hg) | ISMN ER | Amlodipine | Placebo |
|---|---|---|---|
| Change From Baseline (0 Hours) to Week 4 in Central SBP After Multiple Doses of Treatment | -0.7 ± 11.6 | -12.9 ± 11.6 | 3.2 ± 11.6 |
Central DBP was measured by the SphygmoCor® device. Single dose effects on central DBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.
| mm mercury (Hg) | ISMN ER | Amlodipine | Placebo |
|---|---|---|---|
| TWA Change From Baseline (0 Hours) to 12 Hours in Central Diastolic Blood Pressure (DBP) After A Single Dose of Treatment | -8.2 ± 5.9 | -2.1 ± 5.9 | 1.1 ± 5.9 |
Central DBP was measured by the SphygmoCor® device. Central DBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.
| mm mercury (Hg) | ISMN ER | Amlodipine | Placebo |
|---|---|---|---|
| Change From Baseline (0 Hours) to Week 4 in Central DBP After Multiple Doses of Treatment | -0.7 ± 9.0 | -7.7 ± 9.0 | 1.1 ± 9.0 |
Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Single dose effects on peripheral SBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.
| mm mercury (Hg) | ISMN ER | Amlodipine | Placebo |
|---|---|---|---|
| TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral SBP After A Single Dose of Treatment | -12.1 ± 7.7 | -3.1 ± 7.7 | 1.7 ± 7.7 |
Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Peripheral SBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.
| mm mercury (Hg) | ISMN ER | Amlodipine | Placebo |
|---|---|---|---|
| Change From Baseline (0 Hours) to Week 4 in Peripheral SBP After Multiple Doses of Treatment | -0.6 ± 11.2 | -11.4 ± 11.2 | 3.9 ± 11.2 |
Peripheral DBP was measured by Brachial Sphygmomanometer (standard cuff). Single dose effects on peripheral DBP were estimated as a time-weighted average change from baseline over the 12-hour post single dose observation period.
| mm mercury (Hg) | ISMN ER | Amlodipine | Placebo |
|---|---|---|---|
| TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral DBP After A Single Dose of Treatment | -8.0 ± 5.7 | -2.0 ± 5.7 | 1.0 ± 5.7 |
Peripheral SBP was measured by Brachial Sphygmomanometer (standard cuff). Peripheral DBP was measured at baseline and at 24 hours post dose on Day 28 (Week 4) and expressed as a change from baseline.
| mm mercury (Hg) | ISMN ER | Amlodipine | Placebo |
|---|---|---|---|
| Change From Baseline (0 Hours) to Week 4 in Peripheral DBP After Multiple Doses of Treatment | -1.4 ± 8.7 | -7.5 ± 8.7 | 1.0 ± 8.7 |
Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/34 (0%) | 7/34 (20.6%) |
| ISMN ER | — | 0/38 (0%) | 18/38 (47.4%) |
| Amlodipine | — | 0/37 (0%) | 9/37 (24.3%) |
| Event | Placebo | ISMN ER | Amlodipine |
|---|---|---|---|
| HeadacheNervous system disorders | 6/34 | 16/38 | 6/37 |
| Tension HeadacheNervous system disorders | 2/34 | 1/38 | 0/37 |
| NauseaGastrointestinal disorders | 0/34 | 2/38 | 2/37 |
| VomitingGastrointestinal disorders | 1/34 | 1/38 | 2/37 |
| Oedema PeripheralGeneral disorders | 0/34 | 0/38 | 2/37 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 49 ± 7.05 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 11 |
| Male | 22 |
No study locations are listed for this record.
The record gives a start of May 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amlodipine · Isosorbide mononitrate